Skip to main content
Log in

Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

Objective

the aim of the study was to assess the bioavailability of estradiol (E2) following oral, single-dose administration of equimolar doses of three HRT preparations in a 3-way cross-over study in postmenopausal women.

Methods

18 healthy subjects were enrolled. Free E2 and estrone (E1) serum concentrations were determined using commercially available immunoassay kits. Bioequivalence testing was performed between the following oral formulations: (a) 1.5 mg E2 tablets versus 2 mg E2 V tablets; and (b) 1.5 mg E2 plus 0.15 mg DSG tablets versus 1.5 mg E2 tablets.

Results

for both E2 and E1, the E2 tablet was bioequivalent with both the E2 V and the E2/DSG tablet with respect to the rate and extent of absorption (bioavailability). Although the meant tmax values of the three tablet formulations were similar, the variability was too large to prove formal bioequivalence.

Conclusion

E2 tablets and E2/DSG tablets were bioequivalent and also bioequivalence of E2 tablets with commercially available E2 V was found, which ensures a sequential HRT preparation without large variations in estrogen serum concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Borglin N.E., Staland B. (1975): Oral treatment of menopausal symptoms with natural estrogens. Acta Obstet. Gynecol. Scand., 43: 1–11.

    Article  Google Scholar 

  2. Clisham P.R., Ziegler D. de, Lozano K., Judd H.J. (1991): Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women. Obstet. Gynecol., 77: 241–246.

    Article  PubMed  CAS  Google Scholar 

  3. Christiansen C., Christiansen M.S., Larsen N.E., Transbol I. (1982): Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J. Clin. Endocrinol. Metab., 55: 1124–1130.

    Article  PubMed  CAS  Google Scholar 

  4. Mazess R.B., Gallagher J.C., Notelovitz M., Schiff I., Utian W. (1989): Monitoring skeletal response to estrogen. Am. J. Obstet. Gynecol., 161: 843–848.

    PubMed  CAS  Google Scholar 

  5. Lufkin E.G., Carpenter P.C., Ory S.J., Malkasian G.D., Edmonson J.H. (1988): Estrogen replacement therapy; current recommendations. Mayo Clin. Proc., 63: 453–460.

    PubMed  CAS  Google Scholar 

  6. Whitehead M.I., King R.J.B., McQueen I., Campbell S. (1979): Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestagen therapy. J. R. Soc. Med., 72: 322–327.

    PubMed  CAS  Google Scholar 

  7. Whitehead M.I., Townsend P.T., Pryse-Davies J., Ryder T.A., King R.J.B. (1981): Effects of estrogen and progestins on the biochemistry and morphology of the postmenopausal endometrium. N. Engl. J. Med., 305: 1599–1605.

    Article  PubMed  CAS  Google Scholar 

  8. Persson I., Adami H-O., Bergkvist L.et al. (1989): Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ, 298: 147–151.

    Article  PubMed  CAS  Google Scholar 

  9. Gambrell R.D. (1986): Prevention of endometrial cancer with progestogens. Maturitas, 8: 169–176.

    Article  PubMed  Google Scholar 

  10. Saure A., Hirvonen E., Tikkanen M.J., Viinikka L., Ylikorkala O. (1993): A novel oestradiol-desogestrel preparation for hormone replacement therapy; effects on hormones, lipids, bone, climacteric symptoms and endometrium. Maturitas, 16: 1–12.

    Article  PubMed  CAS  Google Scholar 

  11. Marslew U., Riis B.J., Christiansen C. (1991): Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur. J. Clin. Invest., 21: 601–607.

    Article  PubMed  CAS  Google Scholar 

  12. Chen M.L. (1992): Guidance statistical procedures for bioequivalence studies using a standard two-treatment cross-over design, Division of Bioequivalence, Office of Generic Drugs (OGD) of the FDA, informal communication 21 CFR 10.90 (b) (9), July.

  13. International harmonization and consensus DIA meeting on bioavailability and bioequivalence testing requirements and standards. (1991): Drug Inform. J., 25: 471–482.

    Google Scholar 

  14. Steinijans V.W., Diletti E. (1983): Statistical analysis of bioavailability studies. Eur. J. Clin. Pharmacol., 23: 127–136.

    Article  Google Scholar 

  15. Winer B.J. (1971): Statistical principles in experimental design. 2nd edn. New York: McGraw-Hill, 693–696.

    Google Scholar 

  16. Reynolds J.E.F. (1982): Martindale, 28th edn; London: Pharmaceutical Press, 1425–1427.

    Google Scholar 

  17. Midha K.K. (1990): Bio-International 1989. Int. J. Pharm. 4: 101–103.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Timmer, C.J., Geurts, T.B.P. Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study. Eur. J. Drug Metab. Pharmacokinet. 24, 47–53 (1999). https://doi.org/10.1007/BF03190010

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190010

Keywords

Navigation